$SPTY
SPECIFICITY, INC.

2023 Q2 Form 10-Q Financial Statement

#000152013823000242 Filed on May 18, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $279.2K $231.1K $270.9K
YoY Change -26.27% -14.67%
Cost Of Revenue $143.0K $94.21K $150.9K
YoY Change 29.57% -37.57%
Gross Profit $136.2K $136.9K $120.0K
YoY Change -49.24% 14.13%
Gross Profit Margin 48.78% 59.24% 44.29%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $2.583K $2.246K
YoY Change 15.0%
% of Gross Profit 1.89% 1.87%
Operating Expenses $498.8K $587.6K $1.444M
YoY Change -20.63% -59.29%
Operating Profit -$362.6K -$450.7K -$1.324M
YoY Change 0.69% -65.95%
Interest Expense $70.65K $18.10K $10.55K
YoY Change 466.74% 71.6%
% of Operating Profit
Other Income/Expense, Net -$70.65K -$18.10K -$10.55K
YoY Change 466.74% 71.6%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$433.3K -$468.8K -$1.334M
YoY Change 16.28% -64.86%
Net Earnings / Revenue -155.18% -202.84% -492.57%
Basic Earnings Per Share -$0.04
Diluted Earnings Per Share -$0.04
COMMON SHARES
Basic Shares Outstanding 10.62M shares 10.62M shares
Diluted Shares Outstanding 10.68M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $8.711K $50.09K $344.7K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $44.00K
Other Receivables
Total Short-Term Assets $61.57K $158.8K
YoY Change 68.47%
LONG-TERM ASSETS
Property, Plant & Equipment $65.53K $68.14K
YoY Change -12.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $109.4K $122.4K
YoY Change -31.63%
TOTAL ASSETS
Total Short-Term Assets $61.57K $158.8K
Total Long-Term Assets $109.4K $122.4K
Total Assets $170.9K $281.3K
YoY Change -13.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $233.2K $90.11K
YoY Change 7043.22%
Accrued Expenses $41.17K $33.58K
YoY Change -31.48%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.012M $653.4K
YoY Change 426.65%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.012M $653.4K
Total Long-Term Liabilities
Total Liabilities $2.012M $1.663M
YoY Change 63.02%
SHAREHOLDERS EQUITY
Retained Earnings -$7.729M -$7.270M
YoY Change 85.63%
Common Stock $10.68K $10.68K
YoY Change 14.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.841M -$1.382M -$661.2K
YoY Change
Total Liabilities & Shareholders Equity $170.9K $281.3K
YoY Change -13.02%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$433.3K -$468.8K -$1.334M
YoY Change 16.28% -64.86%
Depreciation, Depletion And Amortization $2.583K $2.246K
YoY Change 15.0%
Cash From Operating Activities -$326.9K -$736.7K
YoY Change -55.62%
INVESTING ACTIVITIES
Capital Expenditures $9.207K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$9.207K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $354.2K $452.7K
YoY Change -21.76%
NET CHANGE
Cash From Operating Activities -$326.9K -$736.7K
Cash From Investing Activities -$9.207K
Cash From Financing Activities $354.2K $452.7K
Net Change In Cash $27.27K -$293.1K
YoY Change -109.3%
FREE CASH FLOW
Cash From Operating Activities -$326.9K -$736.7K
Capital Expenditures $9.207K
Free Cash Flow -$326.9K -$745.9K
YoY Change -56.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001840102
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
CY2023Q1 us-gaap Increase Decrease In Notes Receivable Related Parties
IncreaseDecreaseInNotesReceivableRelatedParties
usd
CY2022Q1 us-gaap Increase Decrease In Notes Receivable Related Parties
IncreaseDecreaseInNotesReceivableRelatedParties
usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2022Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
usd
CY2022Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
CY2023Q1 spty Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2023Q1 spty Right Of Use Asset And Liability
RightOfUseAssetAndLiability
usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
333-257323
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
SPECIFICITY, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-4017786
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
410 S. Ware Blvd.
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 508
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Tampa
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33619
CY2023Q1 dei City Area Code
CityAreaCode
(813)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
364-4744
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q1 dei Trading Symbol
TradingSymbol
SPTY
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10624243 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50089 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22818 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8182 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
108759 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
235375 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
158848 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
266375 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
68139 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
70722 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
54276 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
64632 usd
CY2023Q1 us-gaap Assets
Assets
281263 usd
CY2022Q4 us-gaap Assets
Assets
401729 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
90114 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
93867 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33576 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
37828 usd
CY2023Q1 spty Accrued Interest Related Party
AccruedInterestRelatedParty
12500 usd
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
104770 usd
CY2023Q1 spty Related Party Advances
RelatedPartyAdvances
368172 usd
CY2022Q4 spty Related Party Advances
RelatedPartyAdvances
193739 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
44233 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
43909 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
653365 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
369343 usd
CY2023Q1 spty Related Party Notes Payable
RelatedPartyNotesPayable
1000000 usd
CY2022Q4 spty Related Party Notes Payable
RelatedPartyNotesPayable
1000000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10043 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20723 usd
CY2023Q1 us-gaap Liabilities
Liabilities
1663408 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1390066 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10682584 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10682584 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10652584 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10652584 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
10682 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
10652 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4476383 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4401413 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7270210 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6801402 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1382145 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-988337 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
281263 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
401729 usd
CY2023Q1 us-gaap Revenues
Revenues
231118 usd
CY2022Q1 us-gaap Revenues
Revenues
270850 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
94205 usd
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
150890 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
136913 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
119960 usd
CY2023Q1 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
10080 usd
CY2022Q1 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
12880 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
137356 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
600000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
561041 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1335129 usd
CY2023Q1 us-gaap Officers Compensation
OfficersCompensation
16500 usd
CY2022Q1 us-gaap Officers Compensation
OfficersCompensation
95530 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
587621 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
1443539 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-450708 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1323579 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
18100 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
10548 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18100 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10548 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-468808 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1334127 usd
CY2023Q1 spty Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-0.04
CY2022Q1 spty Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-0.15
CY2023Q1 spty Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
10652584 shares
CY2022Q1 spty Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
8875895 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-988337 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
75000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-468808 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1382145 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-468808 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1334127 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
137356 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
600000 usd
CY2023Q1 us-gaap Depreciation
Depreciation
2583 usd
CY2022Q1 us-gaap Depreciation
Depreciation
2246 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8182 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10740 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
11349 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3753 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
42646 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4252 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-36079 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-326932 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-736663 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9207 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9207 usd
CY2023Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
104770 usd
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
174433 usd
CY2022Q1 spty Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
-19246 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
75000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
471967 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
354203 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
452721 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
27271 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-293149 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22818 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
637841 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50089 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
344692 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
3100 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
10548 usd
CY2022Q1 spty Right Of Use Asset And Liability
RightOfUseAssetAndLiability
104665 usd
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_807_eus-gaap--NatureOfOperations_z0v4UQ3X29je" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_82A_zjkTa5xyUwLk">ORGANIZATION AND DESCRIPTION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specificity, Inc. (the “Company”) is a Nevada Corporation incorporated on November 25, 2020 (“Inception”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a full-service digital marketing firm that delivers cutting-edge marketing solutions to business-to-business clients as well as business to consumer clients. The Company has developed tools that allow us to identify and market to people who are actively in the buying cycle. We take advantage of the real-time messaging opportunities digital marketing offers to give small and medium-sized businesses a fair chance at online traffic.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zaFpfBxTErK4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_868_z5ovIUBw2DUj">Use of Estimates</span></span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zn6dLaMdJ435" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_86E_zxFojrOqQkA1">Concentration of Credit Risk</span></span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits of $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_c20230331_pp0p0" title="FDIC limit">250,000</span> per institution that pays Federal Deposit Insurance Corporation (“FDIC”) insurance premiums. The Company has never experienced any losses related to these balances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/>
CY2023Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-468808 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-326932 usd
CY2020Q4 us-gaap Payments To Acquire Software
PaymentsToAcquireSoftware
50000 usd
CY2023Q1 spty Related Party Advances
RelatedPartyAdvances
368172 usd
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
104665 usd
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
104665 usd
CY2023Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.03 pure
CY2023Q1 spty Amounts Due To Related Party
AmountsDueToRelatedParty
15000 usd
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001520138-23-000242-index-headers.html Edgar Link pending
0001520138-23-000242-index.html Edgar Link pending
0001520138-23-000242.txt Edgar Link pending
0001520138-23-000242-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
spec-20230331_10q.htm Edgar Link pending
spec-20230331_10qex31z1.htm Edgar Link pending
spec-20230331_10qex32z1.htm Edgar Link pending
spty-20230331.xsd Edgar Link pending
spty-20230331_def.xml Edgar Link unprocessable
spty-20230331_cal.xml Edgar Link unprocessable
spty-20230331_lab.xml Edgar Link unprocessable
spty-20230331_pre.xml Edgar Link unprocessable
spec-20230331_10q_htm.xml Edgar Link completed